Although lithium continues to be regarded as the treatment of choice for bipolar disorders, the clinical use of this mood stabiliser is associated with an extremely narrow therapeutic range. Relatively minor increases in serum concentrations may induce serious adverse sequelae, and concentrations within the therapeutic range may result in toxic reactions. The safety of combining lithium with other medications, therefore, is a major concern, and extensive clinical experience has served to identify several significant drug interactions.
Lithium removal from the body is achieved almost exclusively via renal means. As a result, any medication that alters glomerular filtration rates or affects electrolyte exchange in the nephron may influence the pharmacokinetic disposition of lithium. Concomitant use of diuretics has long been associated with the development of lithium toxicity, but the risk of significant interactions varies with the site of pharmacological action of the diuretic in the renal tubule. Thiazide diuretics have demonstrated the greatest potential to increase lithium concentrations, with a 25 to 40% increase in concentrations often evident after initiation of therapy. Osmotic diuretics and methyl xanthines appear to have the opposite effect on lithium clearance and have been advocated historically as antidotes for lithium toxicity. Loop diuretics and potassium-sparing agents have minor variable effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have also been associated with lithium toxicity, although the relative interactive potential of specific NSAIDs is difficult to determine. Small prospective studies have demonstrated large interindividual differences in lithium clearance values associated with different NSAIDs. A growing body of evidence also suggests that ACE inhibitors may impair lithium elimination, but further investigations are needed to identify patients at risk.
Anecdotal reports have linked numerous medications with the development of neurotoxicity without an apparent effect on the pharmacokinetic disposition of lithium. Antipsychotics, anticonvulsants and calcium antagonists have all been implicated in a sufficient number of case reports to warrant concern. As these medications have all been commonly coadministered with lithium, the relative risk of serious interactions appears to be quite low, but caution is advised.
Lithium Adis International Limited Amiloride Neuroleptic Malignant Syndrome Lithium Concentration
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Jefferson JW. Lithium: the present and future. J Clin Psychiatry 1995; 56: 41–8Google Scholar
Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349–52PubMedGoogle Scholar
Corcoran AC, Taylor RD, Page IH. Lithium poisoning from the use of salt substitutes. JAMA 1949; 139: 685–8Google Scholar
Schou M, Baastrup PC. Lithium treatment of manic-depressive disorder: dosage and control. JAMA 1967; 201: 696–8PubMedGoogle Scholar
Singer I. Lithium in mania. Clin Pharmacol Ther 1970; 11: 168–87Google Scholar
Meltzer HL. Mode of action of lithium in affective disorders: an influence on intracellular calcium functions. Pharmacol Toxicol 1990; 66 Suppl. 3: 84–99PubMedGoogle Scholar
Holstein-Rathlou N-H. Lithium transport across biological membranes. Kidney Int 1990; 28 Suppl.: S4–9Google Scholar
Price LH, Charney DS, Delgado PL, et al. Lithium and serotonin function: implication for the serotonin hypothesis of depression. Psychopharmacology 1990: 100: 3–12PubMedGoogle Scholar
Odagaki Y, Koyama Y, Yamashita I. Lithium and serotonergic neural transmission: a review of pharmacological and biochemical aspects in animal studies. Lithium 1992; 3: 95–107Google Scholar
Risby ED, Hsiao JK, Mahji HK, et al. The mechanism of lithium action. II. Effects on adenyl cyclase activity and beta adrenergic receptor binding in normal subjects. Arch Gen Psychiatry 1991; 48: 513–24PubMedGoogle Scholar
Dilsaver SC. Lithium’s effects on muscarinic receptor binding parameters: a relationship to therapeutic efficacy? Biol Psychiatry 1984; 19: 1551–65PubMedGoogle Scholar
Baraban J. Toward a crystal-clear view of lithium’s site of action. Proc Natl Acad Sci USA 1994; 91: 5738–9PubMedGoogle Scholar
Coppen A, Abou-Saleh M, Millen P, et al. Decreasing lithium dosage reduces morbidity and side effects during prophylaxis. J Affect Disord 1983; 5: 353–62PubMedGoogle Scholar
Gelenberg AJ, Wojcik JD, Falk WE, et al. Effects of lithium on the kidney. Acta Psychiatr Scand 1987; 75: 29–34PubMedGoogle Scholar
Hestbeck J, Hansen HE, Amdisen A, et al. Chronic renal lesions following long term treatment with lithium. Kidney Int 1977; 12: 305–13Google Scholar
Solomon JG. Lithium toxicity precipitated by a diuretic. Psychosomatics 1980; 21: 425–9PubMedGoogle Scholar
Kerry RJ, Ludlow JM, Owen G. Lesson of the week — diuretics are dangerous with lithium. BMJ 1980; 281: 371PubMedGoogle Scholar
Levy ST, Forrest JN, Heninger GR. Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates, and chlorothiazide treatment. Am J Psychiatry 1973; 130: 1014–8PubMedGoogle Scholar
Poust RI, Mallinger AG, Mallinger J, et al. Effect of chlorothiazide on the pharmacokinetics of lithium in plasma and erythrocytes. Psychopharmacol Commun 1976; 2: 273–84PubMedGoogle Scholar
Jefferson JW, Kalin NH. Serum lithium levels and long-term diuretic use. JAMA 1979; 241: 1134–6PubMedGoogle Scholar
Crabtree BL, Mack JE, Johnson CD, et al. Comparison of the effects of hydrochlorothiazide and furosemide on lithium disposition. Am J Psychiatry 1991; 148: 1060–3PubMedGoogle Scholar
Jakobsson B, Berg U. Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus. Acta Paediatr 1994; 83: 522–5PubMedGoogle Scholar
Himmelhoch JM, Poust RI, Mallinger AG, et al. Adjustment of lithium dose during lithium-chlorothiazide therapy. Clin Pharmacol Ther 1977; 22: 225–7PubMedGoogle Scholar
Hertig HI, Dyson WL. Lithium toxicity enhanced by diuretics. N Engl J Med 1974; 290: 748–9Google Scholar
Baer L, Platman SR, Kassir S, et al. Mechanisms of lithium handling and their relationship to mineralocorticoids: a disassociation between sodium and lithiumions. J Psychiatr Res 1971; 8: 91–105PubMedGoogle Scholar
Batlle DC, von Riotte AB, Gaviria M, et al. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312: 408–14PubMedGoogle Scholar
Kosten TR, Forrest JN. Treatment of severe lithium-induced polyuria with amiloride. Am J Psychiatry 1986; 143: 1563–8PubMedGoogle Scholar
Thomsen K, Leysac PP. Acute effects of various diuretics on lithium clearance. Renal Physiol 1986; 9: 1–8PubMedGoogle Scholar
Perry PJ, Calloway RA, Cook BL, et al. Theophylline precipitated alterations of lithium clearance. Acta Psychiatr Scand 1984; 69: 528–37PubMedGoogle Scholar
Holstad SG, Perry PJ, Kathol RG, et al. The effects of intravenous theophylline infusion on lithium clearance in normal subjects. Psychiatr Res 1988; 25: 203–11Google Scholar
Furlong FW. Possible psychiatric significance of excesssive coffee consumption. Can Psychiatr Assoc J 1975; 20: 577–83PubMedGoogle Scholar
Bikin D, Conrad KA, Mayersohn M. Lack of influence of caffeine and aspirin on lithium elimination [abstract]. Clin Res 1982; 30: 249AGoogle Scholar
Mester R, Toren P, Mizrachi I, et al. Caffeine withdrawal increases lithium blood levels. Biol Psychiatry 1995; 37: 348–50PubMedGoogle Scholar
Douste-Blazy P, Rostin M, Livarek B, et al. Angiotensin-con-verting enzyme inhibitors and lithium treatment [letter]. Lancet 1986; 1: 1448PubMedGoogle Scholar
Mahieu M, Houvenagel E, Leduc JJ, et al. Lithium inhibitors of converting-enzyme, an association to be avoided [letter]. Presse Med 1988; 17: 281PubMedGoogle Scholar
Pulik M, Lida H. Interaction between lithium and angiotensin-converting enzyme inhibitors [letter]. Presse Med 1988; 17: 755PubMedGoogle Scholar
Conrad AJ. Ace inhibitors and lithium toxicity. Mass Gen Hosp Newslett 1988; 2: 43Google Scholar
Navis GJ, de Jong PE, de Zeeuw D. Volume homeostasis, angiotensin-converting enzyme inhibition, and lithium therapy [letter]. Am J Med 1989; 86: 621PubMedGoogle Scholar
Drouet A, Bouvet O. Lithium et inhibitors de l’enzyme de conversion. Encephale 1990; 16: 51–2PubMedGoogle Scholar
Baldwin CM, Safferman AZ. A case of lisinopril-induced lithium toxicity. DICP 1990; 24: 946–7PubMedGoogle Scholar
Holstad HG, Perry PJ, Kathol RG, et al. The effects of i.v. theophylline infusion versus i.v. sodium bicarbonate infusion on lithium clearance in normal subjects [reprint]. Psychiatr Res 1988; 25: 203–11Google Scholar